• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Taiwan·Healthcare·1760.TW
Share

Panion & Bf Biotech Inc. Stocks

NT$ 54.4Last Updated 30.09.2026

Issuer Rating

4/7
Performance

Favourable

Risk

Considerable

Recommendation

Hold

Market Cap

NT$ 145.26M

NT$ 54.4
Key Takeaways

Risk factor

Very poor trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Decent dividends

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Panion & Bf Biotech Inc. is a biopharmaceutical firm operating in Taiwan, engaged in the production and distribution of a diverse range of pharmaceutical goods. Its offerings cater to several key therapeutic and wellness segments, including medical aesthetics, renal care, respiratory health, and gastrointestinal support. Beyond these, the company also provides oral medications, topical treatments, and an array of hygiene products like hand, mechanical, and skin disinfectants, alongside body lotions. Additionally, Panion & Bf Biotech supplies veterinary health solutions, notably surgical and dermatological prescriptions for animals. Established in 1976, the company maintains its corporate headquarters in Taipei, Taiwan.

Company Valuation

Fairly valued
4/7

Considering past and projected metrics, the stock is neither 'expensive' nor 'cheap' compared to its peers. In particular, the stock is reasonably priced on P/E, of fair

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

30.09.2026 13:51

DeepSeek has released tools for Huawei chips that could replace Nvidia's solutions

30.09.2026 13:04

The "Copper" Rally: Three Small-Cap Stocks Outperform a Sector Fund. What Will Drive Their Growth?

30.09.2026 12:01

The dollar has come close to its best performance in a month since June. What does the Fed's interest rate have to do with this?

30.09.2026 11:29

AI for Everyone: Robinhood Will Let Retail Investors Let Bots Trade Stocks on Their Behalf

30.09.2026 10:23

Top Stories This Morning: OpenAI Is Seeking $30 Billion; Trump Agrees on Industry Rules With AI Leaders

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026